Home›Trial›NCT06066580
NCT06066580Phase 2ENROLLING BY INVITATION

Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy

Study Summary

EDG-5506-203 MESA is an open-label extension study to assess the long-term effect of sevasemten (EDG-5506) on safety, biomarkers, and functional measures in adults and adolescents with Becker muscular dystrophy

Conditions
Becker Muscular Dystrophy
Interventions / Drugs
Sevasemten
View on ClinicalTrials.gov ↗
Sponsor
EWTX
Edgewise Therapeutics
Cardiomyopathy
D43/100
Study Details
Enrollment260 participants
Primary Completion—
Lead SponsorEdgewise Therapeutics, Inc.
Data Retrieved2026-04-11 04:13:37.458714+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 2 trials begin testing efficacy in a larger patient group (100–300). This is often where biotech binary events occur — positive Phase 2 data can significantly advance a company's pipeline narrative, while failures can be terminal for a program.

Status & Expected Data

Current status: ENROLLING BY INVITATION.

Enrolled: 260 participants
Sponsor Catalyst Profile

Edgewise Therapeutics (EWTX) is the sponsoring company for this trial. BiotechSign currently grades this company D (43/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

EWTX Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.